US Patent 10392350 N-substituted pyrazolyl guanidine F
Patent 10392350 was granted and assigned to Lycera on August, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+257 characters)
Article
Patent abstract
The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
103923500
Date of Patent
August 27, 2019
0Patent Application Number
158963780
Date Filed
February 14, 2018
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
103923500
Date of Patent
August 27, 2019
0Patent Application Number
158963780
Date Filed
February 14, 2018
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 28 Jan, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10392350 N-substituted pyrazolyl guanidine F
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10392350
Date of patent
August 27, 2019
Patent application number
15896378
Date Filed
February 14, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 10392350 N-substituted pyrazolyl guanidine F
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.